The invention provides an associative polymer, a powder, and a process for making a powder including, networking one or more associative polymers and one or more optional surfactants to form a wet gel, and forming a powder from the wet gel, wherein the associative polymer(s) have a weight average molecular weight of from about 10 kDa to about 2,000 kDa.

The invention provides an associative polymer, a powder, and a process for making a powder including, networking one or more associative polymers and one or more optional surfactants to form a wet gel, and forming a powder from the wet gel, wherein the associative polymer(s) have a weight average molecular weight of from about 10 kDa to about 2,000 kDa.

The present invention relates to tetrahydropyran and thiopyran derivatives having dual pharmacological activity towards both the sigma () receptor, and the -opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Detergents and cleaning agents containing an anionic surfactant of general formula (I), in which n is a number from 5 to 21 and X.sup.+ is a charge-balancing cation. Also disclosed are an agent or a use, characterized in that, in the compound of general formula (I), X.sup.+ is selected from the group including the proton, alkali metal cations and the group N.sup.+R.sup.1R.sup.2R.sup.3, where R.sup.1, R.sup.2 and R.sup.3 are, independently of one another, hydrogen, an alkyl group with 1 to 6 C atoms or a hydroxyalkyl group with 2 to 6 C atoms.

Detergents and cleaning agents containing an anionic surfactant of general formula (I), in which n is a number from 5 to 21 and X.sup.+ is a charge-balancing cation. Also disclosed are an agent or a use, characterized in that, in the compound of general formula (I), X.sup.+ is selected from the group including the proton, alkali metal cations and the group N.sup.+R.sup.1R.sup.2R.sup.3, where R.sup.1, R.sup.2 and R.sup.3 are, independently of one another, hydrogen, an alkyl group with 1 to 6 C atoms or a hydroxyalkyl group with 2 to 6 C atoms.

An electrolyte containing a solvent including at least one compounds of formula I, wherein A.sub.1 is an oxygen atom or a single bond, A.sub.2 is a single bond or CHR.sub.4, R.sub.1 and R.sub.2 are each independently a hydrogen atom, C1-6 alkyls or a C1-6 fluoroalkyls, R.sub.3 and R.sub.4 are each independently a hydrogen atom, a fluorine atom, C1-6 alkyls or C1-6 fluoroalkyls, A1 and A2 cannot both be single bonds simultaneously, and only one of R.sub.1 to R.sub.4 includes a fluorine atom is described. The electrolyte can make a metal negative electrode secondary battery have good cycling performance and good discharge capacity retention at low temperature.

##STR00001##

An electrolyte containing a solvent including at least one compounds of formula I, wherein A.sub.1 is an oxygen atom or a single bond, A.sub.2 is a single bond or CHR.sub.4, R.sub.1 and R.sub.2 are each independently a hydrogen atom, C1-6 alkyls or a C1-6 fluoroalkyls, R.sub.3 and R.sub.4 are each independently a hydrogen atom, a fluorine atom, C1-6 alkyls or C1-6 fluoroalkyls, A1 and A2 cannot both be single bonds simultaneously, and only one of R.sub.1 to R.sub.4 includes a fluorine atom is described. The electrolyte can make a metal negative electrode secondary battery have good cycling performance and good discharge capacity retention at low temperature.

##STR00001##

The present invention relates to the use cyclic-di-nucleotide and related scaffold molecules that measurably inhibit STING signaling, and methods for their use in identifying more potent inhibitors of STING signaling. In particular, the methods provided can be used to identify potent inhibitors of STING signaling, which are useful in the treatment of autoimmune and inflammatory diseases. Also provided are compounds having STING inhibitory activity useful in the treatment of autoimmune and inflammatory diseases.

The present invention relates to the use cyclic-di-nucleotide and related scaffold molecules that measurably inhibit STING signaling, and methods for their use in identifying more potent inhibitors of STING signaling. In particular, the methods provided can be used to identify potent inhibitors of STING signaling, which are useful in the treatment of autoimmune and inflammatory diseases. Also provided are compounds having STING inhibitory activity useful in the treatment of autoimmune and inflammatory diseases.

The disclosure provides an associative polymer, a powder, a process for forming a paper sheet, and a process for making a powder. One or more associative polymers and one or more optional surfactants may be networked to form a wet gel and a powder may be formed from the wet gel. The associative polymer may have a weight average molecular weight of from about 10 kDa to about 2,000 kDa. A method may involve adding the powder to a cellulose fiber slurry, draining the cellulose fiber slurry to form a fiber pad, and drying the fiber pad to form a paper sheet.